surinabant surinabant surinabant (sr147778) is a cannabinoid receptor type 1 antagonist developed by sanofi-aventis. it is being investigated as a potential treatment for nicotine addiction, to assist smoking cessation. it may also be developed as an anorectic drug to assist with weight loss, however there are already several cb1 antagonists or inverse agonists on the market or under development for this application, so surinabant is at present mainly being developed as an anti-smoking drug, with possible application in the treatment of other addictive disorders such as alcoholism. other potential applications such as treatment of adhd have also been proposed. surinabantclinical dataatc codenoneidentifiers iupac name 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-n-(1-piperidinyl)-1h-pyrazole-3-carboxamide cas number288104-79-0 npubchem cid9849616chemspider8025329 yuniisf8r9vcb0xchemblchembl189676 ycomptox dashboard (epa)dtxsid2047357 chemical and physical dataformulac23h23brcl2n4omolar mass522.27 g·mol−13d model (jsmol)interactive image smiles o=c(nn1ccccc1)c4nn(c2ccc(cl)cc2cl)c(c3ccc(br)cc3)c4cc inchi inchi=1s/c23h23brcl2n4o/c1-2-18-21(23(31)28-29-12-4-3-5-13-29)27-30(20-11-10-17(25)14-19(20)26)22(18)15-6-8-16(24)9-7-15/h6-11,14h,2-5,12-13h2,1h3,(h,28,31) ykey:hmxdwdsnprnuki-uhfffaoysa-n y ny (what is this?) (verify) a dose ranging study was done for smoking cessation in 2012; it did not improve success rate, but reduced weight gain. inhibition of thc effects on heart rate was seen at 20 mg and 60 mg but not 5 mg.